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SUMMARY 
A prospective double blind study was conducted to evaluate the role of E.C.T. in schizophrenia. Before 
the start of the trial patients were kept on chlorpromazine in adequate dosage for 30 days. Those who showed fifty 
percent or more improvement during this period were excluded. All patients were given eight modified or 
simulated E.C.T.s. The patients were followed up for one month. E.C.T. did not show any added advantage over 
chlorpromazine either initially or during short term follow-up. 
The role of electroconvulsive therapy 
(ECT) in schizophrenia has remained con-
troversial. Redlich and Freedman (1966) 
stated that ECT should not be used in schi-
zophrenia except in some cases of catatonia. 
There are a number of studies which com-
pared ECT with phenothiazines (Baker et 
al 1958, Langsley et al 1959, Childer's 
1964, Lassenius et al 1973) and ECT phe-
nothiazine combination with phenothia-
zines (Taylor and Fleminger 1980, Jankira-
miah and Subbakrishna 1981, Jankiramiah 
et al 1982). In most of these studies pheno-
thiazines and ECT were administered at 
the same time; phenothiazines require 4-6 
weeks for the onset of anti-psychotic activ-
ity and studies which compare ECT with 
phenothiazines may appear favourable to 
ECT if the phenothiazines are not adminis-
tered for at least 4 weeks before the compa-
rison. Therefore, in the present study we 
planned to administer phenothiazines in 
adequate dosage for 30 days so that at the 
time of comparison with ECT drug activity 
should be at its peak The aim was to evaluate 
whether addition of ECT to phenothiazines 
produces any significant improvement in pa-
tients suffering from schizophrenia. 
Material and Methods 
All schizophrenic patients hospitalized 
under the care of the author (A.K.A.) dur-
ing the study period and fulfilling research 
diagnostic criteria for schizophrenia (Spit-
zer et al 1978) who were in the age range 
of 17 to 50 years were included. Those hav-
ing continuous illness of more than 2 years, 
of less than one month or who had received 
E.C.T. in the past were excluded. In all, fifty 
eight patients were included. Informed 
consent was obtained from the first degree 
relatives of the patients for participation in 
the study. 
The study was divided into three phases 
(a) evaluation (b) comparison and (c) fol-
low-up. During the phase of evaluation all 
patients were kept on chlorpromazine 
600 mg/day in divided dosage. Chlorpro-
mazine has been selected as the representa-
tive of psychotropic drugs as this drug has 
been most widely used in treatment of schi-
zophrenia and is considered to be group re-
presentative. All cases were assessed on 
B.P.R.S. (Overall and Gorham 1962) on day 
1 and later very week. This scale consists of 
16 items which are rated on seven point 
scale. This scale measures changes in the se-
verity of the illness quite effectively. This 
scale has been widely used in clinical trials. 
Patients requiring sedation were given in-
jectable phenobarbitone or diazepam for 
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patients who were unmanageable. At the 
end of one week the dosage of chlorpro-
mazine was increased to 900mg/day, for 
those who were not manageable even on 
900 mg by the end of the second week the 
dosage was increased to 1200mg. At the 
end of four weeks 28 patients showed a re-
duction of more than 50 % in their B.P.R.S. 
score and these were called quick responders. 
The remaining 30 patients were includ-
ed in the phase of comparison. The dosage 
of phenothiazines were kept constant in 
this phase. Fifteen patients were receiving 
600mg/day, eleven 900mg/day and four 
1200 mg/day of chlorpromazine. These pa-
tients were randomly divided into modified 
ECT (M.E.C.T.) and simulated E.C.T. 
groups (S.E.C.T.). The E.C.T. group were 
given E.C.T. (Bitemporal electrode place-
ment) on alternate days to a total of 8 treat-
ments. E.C.T. was given under thiopentone 
anaesthesia with succinylcholine as muscle 
relaxant. The simulated E.C.T. group was 
given only thiopentone anaesthesia but no 
E.C.T. All cases were assessed on B.P.R.S. 
one day after the 3rd, 6th and 8th treatment 
in both the groups. The assessor was blind 
to the mode of treatment. 
Later these 30 patients were followed 
up for one month. They were assessed on 
B.P.R.S. after 15 and 30 days. 
Results 
During the first phase fifty eight pa-
tients were kept on chlorpromazine. At the 
end of 30 days the responder mean B.P.R.S. 
score changed from 55.14 ± 16.28 to 
24.82 ± 3.67. In the non-responders the 
mean B.P.R.S. score changed from 
57.13 ± 9.04 to 49.16 ± 9.89. These non-re-
sponders were then randomly allocated to 
M.E.C.T. and S.E.C.T. groups. 
Table 1 shows the improvement in 
these two treatment groups during the 
phase of treatment and follow-up. The im-
provement in M.E.C.T group became signi-
ficant after 8 treatments while in S.E.C.T 
group the significance was perceptible at 
each step of evaluation. Patients on both 
treatment groups improved significantly. 
To compare the relative efficiency of 
E.C.T. phenothiazines combination over 
phenothiazine analysis of covariance was 
done (Table 2). 
This (Table 2) clearly reveals that there 
Table 1 
Mean of Total BPRS Score at each evaluation 
Baseline 
After 3 treatments 
After 6 treatments 
After 8 treatments 
15 days after stopping 
30 days after stopping 
treatment 
treatment 
Mean 
46.33 
44.13 
42.33 
36.40 
32.20 
30.27 
MECT 
S.D. 
8.25 
7.08 
6.63 
7.02 
7.18 
8.91 
't' Value 
-
1.36 
1.76 
4.88*" 
5.16"* 
4.88*" 
Mean 
52.00 
47.53 
45.00 
42.13 
40.46 
36.60 
SECT 
S.D. 
10.52 
9.04 
9.78 
9.09 
9.32 
9.11 
't' Value 
-
3.56* 
6.11*" 
4.83"* 
5.87*" 
6.96"* 
Treatment stands for MECT or SECT 
All 't' comparisons have d.f. - 14. 
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Table 2 
Adjusted Mean of BPRS Total Score (After Analysis of Covariance at each evaluation) 
Baseline After 3 After 6 After 8 15 days after 30 days after 
score treatments treatments treatments stopping treatment stopping treatment 
MECT 46.33 46.14 44.24 38.07 33.39 31.16 
(N-15) 
SECT 52.00 45.32 43.09 40.25 39.27 35.64 
(N-15) 
F Value - 0.29 0.28 1.05 4.04 1.70 
(NS) (NS) (NS) (NS) (NS) 
Treatment stands for MECT or SECT 
is no statistically significant difference be-
ween the two treatment methods. 
Other variables (family history of schi-
zophrenia, duration of illness, presence of 
Schneiderian first rank symptoms and pres-
ence of depression) were also investigated 
to find out if E.C.T. phenothiazine combi-
nation shows any superiority over pheno-
thiazines alone. Except for depression no 
significant difference was observed on any 
of the above variable. Subject receiving 
E.C.T. showed significantly better impro-
vement on BPRS score of depression at the 
end of follow-up while no such difference 
was visible after 8 treatments (Table-3). 
Table 3 
Adjusted Mean of BPRS score of depression 
(After analysis of Covariance) 
„ ,. After 8 30 days after 
Baseline ' 
treatments stopping treatment 
MECT 2.20 1.65 1.20 
(N-15) 
SECT 2.66 1.88 1.86 
(N-15) 
F. Value - 1.06 5.72* 
Treatment stands for MECT or SECT, 
*p<0.05, df for all F Values = 1, 27. 
Discussion 
Our results are in agreement with most 
of the later well designed studies that 
d.f. for all values = 1, 27 
E.C.T. offers no special advantage in the 
treatment of acute schizophrenia (Janakira-
maiah et all982, Joyce et al 1982, Bagadia 
et al 1983). Taylor and Fleminger (1980) 
showed that E.C.T. phenothiazine combi-
nation shows early superiority to pheno-
thiazine alone, but in this study the dosage 
of phenothiazines was low. Janakiramaiah 
and Subbakirshna (1981) obtained similar 
results when the dosage of chlorpromazine 
was kept at 300 mg/day. Cole and Davis 
(1969) emphasized that the dosage of ch-
lorpromazine should be 500 mg/day if one 
wants to have better results than placebo. 
Studies that compare phenothiazines with 
phenothiazine E.C.T. combination are like-
ly to show superiority of the latter because 
phenothiazines take four to six weeks for 
their antipsychotic activity to be fully evid-
ent (Davis 1980). One month of pheno-
thiazine administration prior to the compa-
rison phase appears to be very important for 
valid comparisons. The present study also 
failed to show any evidence of quicker re-
sponse in patients receiving E.C.T. On the 
other hand, patients receiving E.C.T. 
showed significant improvement only after 
8 E.C.T. while the S.E.C.T group showed 
improvement at each step of evaluation. 
E.C.T. did not produce any benefit on most 
clinical variables except depression. Pa-
tients who score high on depression on 236  ECT PHENOTHIAZINE COMBINATION IN SCHIZOPHRENIA 
B.P.R.S. did show better response with 
E.C.T. at the end of one month of follow-
up. E.C.T.may have a role in depressed schi-
zophrenics. This study may be criticised for 
using only 8 E.C.T., while Wessels (1971) 
suggested that as many as 20 E.C.T. should 
be given. Our patients showed adequate 
improvement with fewer E.C.T. than this. 
E.C.T. does not appear to provide any 
advantage in schizophrenics who are being 
adequately treated with phenothiazines but 
may have value in depressed schizophren-
ics. This study has nothing to say about the 
possible usefulness of E.C.T. in catatonic 
stupor, where it may be life saving. 
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